Med Life SA · BVB:M
Med Life SA — H1 2020 Earnings Presentation
17 slides from Med Life SA's earnings presentation, Aug 14, 2020
Slide 1: H1 2020 Financial Results
H1 2020 Financial Results Conference call presentation 14 August, 2020
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of Med Life SA’s securities, or an offer, invitation or recommendation to sell, or a solicitation of an offer to buy Med Life SA’s securities. Neither this presentat
Slide 3: Agenda
1 • H1 2020 at a glance Highlights H1 2020 • Key messages H1 2020 AGENDA Financial overview • Consolidated Statement of Profit and Loss 2 • • Consolidated Statement of Financial Position Consolidated Statement of Cash Flow Q&A Session 3 3/
Slide 4: Highlights H1 2020
Highlights H1 2020 • H1 2020 at a glance • Key messages H1 2020 1 4/
Slide 5: H1 2020 at a glance (1/5)
H1 2020 at a glance (1/5) Covid-19 outbreak The first case of COVID-19 was officially registered on February 26, 2020. Two months of state of emergency between 16th of March – 14th of May, with strict lockdown restrictions and reduced activity in most economic sectors and, especially, targeted restr
Slide 6: H1 2020 at a glance (2/5)
H1 2020 at a glance (2/5) The activity of the Romanian healthcare system, both public and private, was restricted to emergency services only by Military Ordinances during the state of emergency, with direct impact on traffic in all business lines. Measures were taken by management to limit the negat
Slide 7: H1 2020 at a glance (3/5)
H1 2020 at a glance (3/5) Developments of H1 2020 The development of the three COVID-19 laboratories, in record time, was one of the important achievements of the group in the first half of 2020. Through these, the company was able to keep MedLife employees safe, to periodically test medical and aux
Slide 8: H1 2020 at a glance (4/5)
H1 2020 at a glance (4/5) Developments of H1 2020 (cont.) A dynamic activity was also registered in the area of corporate segment. Since the beginning of the COVID-19 pandemic, the company has developed new products to meet the needs in this epidemiological context, has designed special projects tai
Slide 9: H1 2020 at a glance (5/5): Outlook for 2020
H1 2020 at a glance (5/5) Outlook for 2020 In the second half of the year, the company intends to continue investing in existing programs, but also to develop new projects and products post - COVID. Further development of MedPark project which already started, bringing together the hospital activiti
Slide 10: Key messages H1 2020
Key messages H1 2020 Pro-forma figures Strong Balance Sheet 803m RON Total Non-current assets solid liquidity position 76m RON Cash and cash equivalents 454.6m RON Pro-forma Sales vs. 468m RON in H1 2019 Resilient financial performance 32m RON operating profit stable vs impact of COVID-19 over traff
Slide 11: Financial overview
Financial overview Consolidated Stetement of Profit and Loss Consolidated Statement of Financial Position Consolidated Stetement of Cash Flow 2 11 /
Slide 12: Consolidated Statement of Profit and Loss (1/3)
Consolidated Statement of Profit and Loss (1/3) H1 2020 Pro-forma vs. H1 2019 IFRS ❑ Sales decreased by 2.9%, to 454.6m RON ❑ OPEX decreased by 4.4%, to 424.3m RON ❑ EBIT increased by 13.9% to 32m RON, 7.0% margin (6.0%) ❑ EBITDA increased by 10% to 81.3m RON, 17.9% margin (15.8%) ❑ EBITDA before IF
Slide 13: Consolidated Statement of Profit and Loss (2/3)
Consolidated Statement of Profit and Loss (2/3) Operational KPIs Sales for H1 2020 standing at the level of H1 2019 (on IFRS), and decreasing by near 3% vs H1 2019 (Pro-forma) as an effect of: ➢ Acquisitions made subsequent to H1 2019 ➢ strong operating performance in January and February ➢ drop in
Slide 14: Consolidated Statement of Profit and Loss (3/3)
Consolidated Statement of Profit and Loss (3/3) OPEX Evolution 14 / 1.Highlights 2020 2. Financial overview 3. Q&A Session
Slide 15: Consolidated Statement of Financial Position
Consolidated Statement of Financial Position Net debt to Pro-forma EBITDA ratio 4 3 3.1 3.2 3.3 3.1 3 2 2.6 1 0 2015 2016 2017 2018 2019 H1 2020 15 / 1.Highlights 2020 2. Financial overview 3. Q&A Session
Slide 16: Consolidated Statement of Cash Flow
Consolidated Statement of Cash Flow Cash flow for the period characterized by controls and saving measures: 1. 64% increase in net cash from operating activities; 2. 23% decrease in cash used in investing activities; 3. 88% increase in net cash used in financing activities. 16 / 1.Highlights 2020 2.
Slide 17: Q&A Session - Thank you!
Q&A Session Thank you! 3 17 /